Klinische studies radiotherapie-oncologie

Overzicht van lopende klinische studies op onze dienst

Gastro-intestinale tumoren

  • PROTECT: PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy 
    Contact: prof. dr. K. Haustermans

Hersentumoren

  • NARCiS: Neurocognition after radiotherapy in adult brain and base of skull tumours
    Contact: prof. dr. M. Lambrecht
  • LEGATO: Lomustine with or without reirradiation for first progression of glioblastoma: a randomized phase III study
    Contact: prof.dr. M. Lambrecht

Hoofd- en halstumoren

  • NANORAY-312: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
    Contact: prof. dr. S. Nuyts

Longtumoren

  • LAT-FLOSI: Local ablative therapy for oligoprogressive non-small-cell lung cancer treated with first-line osimertinib.
    Contact: dr. P. Berkovic

Niet-ziekte specifieke studies

  • LAT-MUM: Local ablative therapy for patients with multiple (4-10) brain metastases.
    Contact: dr. P. Berkovic

Prostaattumoren

  • PART: Elective para-aortic radiotherapy (PART) for pN1 prostate cancer: a phase 2 trial using Arc therapy (IMAT / VMAT).
    Contact: prof. dr. G. De Meerleer
  • OBELIX: Observational study on extreme hypofractionation for localized prostate cancer.
    Contact: prof. dr. G. De Meerleer
  • SPARKLE: Metastasis-directed therapy for oligocurrent prostate cancer: a randomized phase III trial.
    Contact: prof. dr. G. De Meerleer
  • MEDCARE: Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
    Contact: prof. dr. G. De Meerleer
  • HYPOFLAME 3.0: Standard moderately hypofractionated radiotherapy vs. ultra-hypofractionated focal lesion ablative microboost in prostate cancer
    Contact: Prof.dr. K. Haustermans
  • STEREOBED: coming soon
    Contact: prof. C. Berghen
Laatste aanpassing: 13 augustus 2025